Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 22;14:479–493. doi: 10.2147/JIR.S292764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Meng et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

HS-induced IL-17a expression was moderated by NMN treatment through SIRT1. (A) The relative expression of IL-17a mRNA in control group, CEC in HS status, NMN-treated CEC in HS status and NMN+Ex527-treated CEC in HS status, n=4, data presented as mean ± SD. One-way ANOVA with SNK multiple comparisons test. ***P<0.001. (B) The supernatant content of IL-17a in control, CEC in HS status, NMN-treated CEC in HS status and NMN+Ex527-treated CEC in HS status, n=4, data presented as mean ± SD. One-way ANOVA with SNK multiple comparisons test. ***P<0.001 (C) The protein levels of SIRT1 and IL-17a in control group, CEC in HS status, NMN-treated CEC in HS status and NMN+Ex527-treated CEC in HS status. n=3, data presented as mean ± SD. One-way ANOVA with SNK multiple comparisons test. **P<0.01; ***P<0.001.